Dataset from Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke

The primary objective of the study is to assess the clinical effects of natalizumab versus
placebo in acute ischemic stroke on clinical measures of functional independence and
activities of daily living. The secondary objective of the study is to explore dose and
exposure response and the clinical treatment effects of natalizumab versus placebo in acute
ischemic stroke on the following: measures of independence, activities of daily living,
neurologic function, quality of life, cognition, and safety and tolerability